What's new? Log in Free sign up

Akcea Therapeutics (AKCA)

Company Profile

Company profile

Ticker

AKCA

Exchange

Website

www.akceatx.com

CEO

Damien McDevitt

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Subsidiaries

Akcea Therapeutics UK Limited • Akcea Therapeutics Canada, Inc. • Akcea Therapeutics France SAS • Akcea Therapeutics Germany GmbH • Akcea Therapeutics Securities Corporation • Akcea Therapeutics Portugal, Unipessoal Lda, a Portuguese Company • Akcea Therapeutics Spain SL, a Spanish Company • Akcea Therapeutics Italia SRL ...

AKCA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Automatic shelf registration (post-effective amendment)

Entry into a Material Definitive Agreement

Going private transaction (amended)

Tender offer solicitation (amended)

Latest ownership filings

View all

Change in insider ownership

MICHAEL DENNIS PRICE

Joshua F. Patterson

Alex G. Howarth

William T. Andrews

Damien McDevitt

MICHAEL J. YANG

Financial summary

Financial statements Chart AKCA financial data

Quarter (USD)	Jun 20	Mar 20	Sep 19	Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	138.13 mm	138.13 mm	138.13 mm	138.13 mm	138.13 mm	138.13 mm
Cash burn (monthly)	9.19 mm	5.44 mm	17.03 mm	13.97 mm	11.14 mm	11.75 mm
Cash used (since last report)	515.50 mm	305.10 mm	955.08 mm	783.48 mm	624.80 mm	659.09 mm
Cash remaining	-377.37 mm	-166.97 mm	-816.95 mm	-645.35 mm	-486.67 mm	-520.96 mm
Runway (months of cash)	-41.1	-30.7	-48.0	-46.2	-43.7	-44.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

AKCA institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1	1	–
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	1.00 k	1.00 k	–
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
IONS Ionis Pharmaceuticals	1.00 k	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
IONS Ionis Pharmaceuticals	1.00 k	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.